Fig. 6
Targeting ETAR with macitentan impairs metastatic formation in vivo by interfering with the ZEB1/YAP signaling. A, B Female nude mice were intraperitoneally (i.p.) injected with OVCAR-3 cells and, after 1 week of latency, were treated with vehicle (Ctr) or MAC (30 mg/kg oral daily) for 5 weeks. Graph (B) represents the number of visible metastasis. Values are the means ± SD (****p < 0.0001). C IB analysis for ZEB1, pYAP (S127), and ILK in total extracts from i.p. nodules of OVCAR-3 xenografts treated as in A. β-actin was used as loading control